Literature DB >> 17047898

Molecular pathology of chondroid neoplasms: part 2, malignant lesions.

W C Bell1, M J Klein, M J Pitt, G P Siegal.   

Abstract

This is the second part of a two-part review presenting an overview of the molecular findings associated with both benign and malignant chondroid neoplasms. The first part presented a brief review of modern methods in molecular pathology, along with a review of the cytogenetic and molecular genetic findings in benign chondroid neoplasms. This second part reviews the cytogenetic and molecular genetic findings in malignant chondroid neoplasms. Clinical aspects of the various lesions are briefly discussed, and each tumor is illustrated with representative radiographic and pathologic images.

Entities:  

Mesh:

Year:  2006        PMID: 17047898     DOI: 10.1007/s00256-006-0217-y

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.199


  62 in total

1.  The EWS/TEC fusion protein encoded by the t(9;22) chromosomal translocation in human chondrosarcomas is a highly potent transcriptional activator.

Authors:  Y Labelle; J Bussières; F Courjal; M B Goldring
Journal:  Oncogene       Date:  1999-05-27       Impact factor: 9.867

2.  Fusion of the EWS-related gene TAF2N to TEC in extraskeletal myxoid chondrosarcoma.

Authors:  H Sjögren; J Meis-Kindblom; L G Kindblom; P Aman; G Stenman
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

3.  The EWS/NOR1 fusion gene product gains a novel activity affecting pre-mRNA splicing.

Authors:  Naganari Ohkura; Hiroko Yaguchi; Toshihiko Tsukada; Ken Yamaguchi
Journal:  J Biol Chem       Date:  2001-10-22       Impact factor: 5.157

4.  Clear cell chondrosarcoma of the larynx: a case report of a rare histologic variant in an uncommon localization.

Authors:  B Kleist; M Poetsch; C Lang; A Bankau; G Lorenz; K Süess-Fridrich; G Jundt; E Wolf
Journal:  Am J Surg Pathol       Date:  2002-03       Impact factor: 6.394

5.  Alterations in the regulatory pathway involving p16, pRb and cdk4 in human chondrosarcoma.

Authors:  J Asp; S Inerot; J A Block; A Lindahl
Journal:  J Orthop Res       Date:  2001-01       Impact factor: 3.494

6.  Identification of a novel fusion gene involving hTAFII68 and CHN from a t(9;17)(q22;q11.2) translocation in an extraskeletal myxoid chondrosarcoma.

Authors:  C Attwooll; M Tariq; M Harris; J D Coyne; N Telford; J M Varley
Journal:  Oncogene       Date:  1999-12-09       Impact factor: 9.867

7.  Chromosomal abnormality t(9;22)(q22;q12) in an extraskeletal myxoid chondrosarcoma characterized by fine needle aspiration cytology, electron microscopy, immunohistochemistry and DNA flow cytometry.

Authors:  C Orndal; B Carlén; M Akerman; H Willén; N Mandahl; S Heim; A Rydholm; F Mitelman
Journal:  Cytopathology       Date:  1991       Impact factor: 2.073

8.  Comparative genomic hybridization in cartilaginous tumors.

Authors:  Toshifumi Ozaki; Daniel Wai; Karl-Ludwig Schäfer; Norbert Lindner; Werner Böcker; Winfried Winkelmann; Barbara Dockhorn-Dworniczak; Christopher Poremba
Journal:  Anticancer Res       Date:  2004 May-Jun       Impact factor: 2.480

9.  Monoclonal antibody to parathyroid hormone-related protein induces differentiation and apoptosis of chondrosarcoma cells.

Authors:  Takahiro Miyaji; Takanobu Nakase; Eturo Onuma; Koh Sato; Akira Myoui; Tetsuya Tomita; Susumu Joyama; Kenta Ariga; Jun Hashimoto; Takafumi Ueda; Hideki Yoshikawa
Journal:  Cancer Lett       Date:  2003-09-25       Impact factor: 8.679

10.  The homeotic protein Six3 is a coactivator of the nuclear receptor NOR-1 and a corepressor of the fusion protein EWS/NOR-1 in human extraskeletal myxoid chondrosarcomas.

Authors:  Cynthia Laflamme; Christine Filion; Julia A Bridge; Marc Ladanyi; Mary B Goldring; Yves Labelle
Journal:  Cancer Res       Date:  2003-01-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.